- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Carlsbad Today
By the People, for the People
Carlsmed Leads Surgical Instrument Peers with AI-Powered Personalized Spine Solutions
Carlsmed's aprevo Technology Platform aims to optimize patient outcomes and reduce revision surgeries through customized surgical plans and implants.
Published on Mar. 6, 2026
Got story updates? Submit your updates here. ›
Carlsmed (NASDAQ:CARL) is a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions. The company's aprevo Technology Platform provides customized surgical plans and interbody implants powered by AI-enabled algorithms to address the limitations of traditional spine fusion surgery. Carlsmed's solutions aim to optimize patient outcomes and reduce the need for revision surgeries, which can impose significant economic burden on the healthcare system.
Why it matters
Carlsmed's approach to spine fusion surgery represents a significant advancement over traditional methods, which often lack robust pre-operative planning and rely on one-size-fits-all implants that fail to match each patient's unique anatomy. By leveraging AI and personalized solutions, Carlsmed aims to improve spinal alignment, reduce complications, and lower the likelihood of revision surgeries, which can cost over $100,000 per procedure.
The details
The aprevo Technology Platform consists of AI-enabled software solutions, custom-designed interbody implants, and single-use surgical instruments. The platform is designed to address the limitations of traditional spine fusion by providing personalized surgical plans and implants tailored to each patient's unique pathology and vertebral bone topography. Carlsmed's solutions are 510(k) cleared by the FDA and commercially available in the U.S. for lumbar interbody fusion surgeries, with plans to expand to cervical fusion procedures in 2026.
- Carlsmed received FDA 510(k) clearance for its aprevo interbody implants for cervical interbody fusion surgeries in November 2024.
- Carlsmed plans to commercialize the aprevo Technology Platform for cervical fusion surgery in 2026.
The players
Carlsmed
A commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions.
What’s next
Assuming Carlsmed gets the necessary additional clearances, the company expects to commercialize the aprevo Technology Platform for cervical fusion surgery in 2026.
The takeaway
Carlsmed's innovative aprevo Technology Platform represents a significant advancement in spine fusion surgery, leveraging AI and personalized solutions to improve patient outcomes and reduce the burden of revision surgeries on the healthcare system.
